Improved growth and cardiovascular risk after late steroid withdrawal: 2-year results of a prospective, randomised trial in paediatric renal transplantation

Nephrology Dialysis Transplantation

Volumn 25, Issue 2, 2010, Pages 617-624

  Höcker, Britta ^a   Weber, Lutz T ^a,b   Feneberg, Reinhard ^a   Drube, Jens ^c   John, Ulrike ^d   Fehrenbach, Henry ^e   Pohl, Martin ^f   Zimmering, Miriam ^g   Fründ, Stefan ^h   Klaus, Günter ^h   Wühl, Elke ^a   Tönshoff, Burkhard ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d JENA UNIVERSITY HOSPITAL   (Germany)

^e Klinikum Memmingen   (Germany)

^f UNIVERSITY OF FREIBURG   (Germany)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Cardiovascular; Metabolic syndrome; Mycophenolate mofetil; Paediatric renal transplantation; Steroid withdrawal

Indexed keywords

ANTIHYPERTENSIVE AGENT; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID;

ACUTE GRAFT REJECTION; ADOLESCENT; ARTICLE; CARBOHYDRATE METABOLISM; CARDIOVASCULAR RISK; CHILD; CHILD GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; GRAFT SURVIVAL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INCIDENCE; KIDNEY TRANSPLANTATION; LIPID METABOLISM; MALE; METABOLIC SYNDROME X; MULTICENTER STUDY; PEDIATRIC SURGERY; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

ADOLESCENT; CARDIOVASCULAR DISEASES; CHILD; CYCLOSPORINE; FEMALE; GLUCOCORTICOIDS; GROWTH; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MYCOPHENOLIC ACID; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 75649122587     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp506     Document Type: Article

References (32)

1. Tönshoff B, Höcker B, Weber LT. Steroid withdrawal in pediatric and adult renal transplant recipients. Pediatr Nephrol 2005; 20: 409-417
2. Sorof JM, Sullivan EK, Tejani A et al. Antihypertensive medication and renal allograft failure: a North American Pediatric Renal Transplant Cooperative Study report. J Am Soc Nephrol 1999; 10: 1324-1330 (Pubitemid 29246999)
3. Lezaic V, Naumovic R, Stanic M et al. Factors affecting graft function in pediatric and adult recipients of adult live donor kidney transplants. Pediatr Transplant 2007; 11: 906-913
4. Weiss R, Dziura J, Burgert TS et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004; 350: 2362-2374
5. Ramirez-Cortes G, Fuentes-Velasco Y, Garćia-Roca P et al. Prevalence of metabolic syndrome and obesity in renal transplanted Mexican children. Pediatr Transplant 2009; 13: 579-584
6. Ingulli E, Tejani AH. Steroid withdrawal after renal transplantation. In: Tejani AH, Fine RN (eds). Pediatric Renal Transplantation. New York: Wiley-Liss, 1994; 221-238
7. Höcker B, John U, Plank C et al. Successful withdrawal of steroids in pediatric renal transplant recipients receiving cyclosporine A and mycophenolate mofetil treatment: results after four years. Transplantation 2004; 78: 228-234
8. Höcker B, Weber LT, Feneberg R et al. Prospective, randomized trial on late steroid withdrawal in pediatric renal transplant recipients under cyclosporine microemulsion and mycophenolate mofetil. Transplantation 2009; 87: 934-941
9. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001; 357: 1191-1194 (Pubitemid 32378696)
10. Extensions of the CONSORT Statement. Available at: http://www. consort-statement.org (June 2009, date last accessed)
11. Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am 1987; 34: 571-590
12. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723 (Pubitemid 29082898)
13. Tanner JM. Growth at Adolescence.Oxford: Blackwell ScientificPub- lications, 2001
14. Prader A, Largo RH, Molinari L et al. Physical growth in Swiss children from birth to 20 years of age. Helv Paediatr Acta Suppl 1989; 52: 1-125
15. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004; 114: 555-576
16. Wilson AC, Greenbaum LA, Barletta GM et al. High prevalence of the metabolic syndrome and associated left ventricular hypertrophy in pediatric renal transplant recipients. Pediatr Transplant 2009; Feb 20. [Epub ahead of print] PMID: 19254245
17. Kromeyer-Hauschild K, Wabitsch M, Kunze D et al. Perzentile für den Body-mass-Index für das Kindes-und Jugendalter unter Her-anziehung verschiedener deutscher Stichproben. Monatsschr Kinder-heilkd 2001; 149: 807-818
18. Schweizer RT, Rovelli M, Palmeri D et al. Noncompliance in organ transplant recipients. Transplantation 1990; 49: 374-377
19. McDonald SP, Craig JC. Australian and New Zealand Pediatric Nephrology Association. Long-term survival of children with end-stage renal disease. N Engl J Med 2004; 350: 2654-2662
20. Koshy SM, Guttmann A, Hebert D et al. Incidence and risk factors for cardiovascular events and death in pediatric renal transplant patients: a single center long-term outcome study. Pediatr Transplant 2008; Dec 9. [Epub ahead of print] PMID: 19077134
21. Vanrenterghem YF, Claes K, Montagnino G et al. Risk factors for cardiovascular events after successful renal transplantation. Transplantation 2008; 85: 209-216
22. Morrison JA, Friedman LA, Wang P et al. Metabolic syndrome in childhood predicts adult metabolic syndrome and type 2 diabetes mellitus 25 to 30 years later. J Pediatr 2008; 152: 201-206
23. Adeseun GA, Rivera ME, Thota S et al. Metabolic syndrome and coronary artery calcification in renal transplant recipients. Transplantation 2008; 86: 728-732
24. Valavi E, Otukesh H, Fereshtehnejad SM et al. Clinical correlation between dyslipidemia and pediatric chronic allograft nephropathy. Pediatr Transplant 2008; 12: 748-754
25. Chang SH, Coates PT, McDonald SP. Effects of body mass index at transplant on outcomes of kidney transplantation. Transplantation 2007; 84: 981-987
26. Opelz G, Döhler B. Collaborative Transplant Study. Improved long-term outcomes after renal transplantation associated with blood pressure control. Am J Transplant 2005; 5: 2725-2731
27. Woodle ES, First MR, Pirsch J et al. Astellas Corticosteroid Withdrawal Study Group. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticos-teroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008; 248: 564-577
28. Opelz G, Döhler B, Laux G. Collaborative Transplant Study. Long-term prospective study of steroid withdrawal in kidney and heart transplant recipients. Am J Transplant 2005; 5: 720-728
29. Sivaraman P, Nussbaumer G, Landsberg D. Lack of long-term benefits of steroid withdrawal in renal transplant recipients. Am J Kidney Dis 2001; 37: 1162-1169
30. Broyer M, Guest G, Gagnadoux MF. Growth rate in children receiving alternate-day corticosteroid treatment after kidney transplantation. J Pediatr 1992; 120: 721-725
31. Jabs K, Sullivan EK, Avner ED et al. Alternate-day steroid dosing improves growth without adversely affecting graft survival or long-term graft function. A report of the North American Pediatric Renal Transplant Cooperative Study. Transplantation 1996; 61: 31-36
32. Sarwal MM, Vidhun JR, Alexander SR et al. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation. Transplantation 2003; 76: 1331-1339